BRAF and neoplasm: Analogously, combined BRAF and MEK targeting (vemurafenib plus cobimetinib or dabrafenib plus trametinib) lead to a significant reduction in tumor maximum standardized uptake value (SUVmax) in patients with advanced melanoma with a mean time to follow-up of 26 days [22].